CME / ABIM MOC / CE

Heart Failure and Myocardial Disease

Authors: Javed Butler, MD, MPH, MBA; Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA; Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC; Nasrien Ibrahim, MD, FACC, FAHA, FHFSA; Martha Kingman, FNP, DNP; Mikhail Kosiborod, MD; Thomas M. Maddox, MD, MSc; Ahmad Masri, MD, MS; Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA; Fatima Rodriguez, MD, MPH, FACC, FAHA; Brett W. Sperry, MD
CME / ABIM MOC / CE Released: 1/4/2023
Valid for credit through: 1/4/2024, 11:59 PM EST

Credits Available

Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.50 ABIM MOC points

Nurses - 2.50 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

IPCE - 2.50 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists and endocrinologists, primary care physicians (PCPs), nephrologists, nurses, nurse practitioners (NPs), physician assistants (PAs) and any other healthcare practitioners (HCPs) involved in the care of patients at risk for cardiovascular (CV) events.

The goal of this activity is that learners will be better able to identify and manage patients with heart failure per new therapeutics and guideline-directed medical therapy (GDMT).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current and emerging therapeutic approaches for the treatment of heart failure (HF) across the spectrum of ejection fractions (EFs)
- Way to provide patient education by the interprofessional care team for improved adherence to guideline recommendations for the management of HF
- Current and emerging treatment options for rare cardiac conditions
Have greater competence related to
- Application of guidelines and evidence to optimize the use of GDMT in the treatment of HF

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Co-Chair

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute
Dallas, Texas, United States
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi, United States

Disclosures

Javed Butler, MD, MPH, MBA, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Adrenomed; Amgen; Applied Therapeutics; Array; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb Company; CVRx; G3 Pharma; Impulse Dynamics; Innolife; Janssen; LivaNova; Luitpold; Medtronic; Merck; Novartis; Novo Nordisk; Relypsa; Roche; Sequana Medical; Vifor Pharma
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Janssen; Lilly; Novartis

Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA

Professor, University of Manitoba
Director, St Boniface Hospital Heart Failure and Transplant Clinics
Head, Medical Heart Failure Program, Cardiac Sciences Manitoba
Immediate Past President, Canadian Heart Failure Society
SPC Chair, Canadian Cardiovascular Congress
Winnipeg, Manitoba, Canada

Disclosures

Shelley Zieroth, MD, FRCPC, FCCS, FHFSA, FESC, FACC, FHFA, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Akcea; AstraZeneca; Amgen; Alnylam; Bayer; Boehringer Ingelheim; Lilly; Merck; Novartis; Novo Nordisk; Otsuka; Pfizer; Servier; Vifor Pharma
Speaker or member of speakers bureau for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; HLS Therapeutics; Janssen; Lilly; Novartis; Servier; Vifor Pharma
Research funding from: Novartis; Servier
Contracted researcher for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Eidos; Merck; Novartis

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC

The Mary and Gordon Cain Chair in Cardiology
Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Associate Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Medicine Chief, DeBakey VA Medical Center
Houston, Texas, United States

Disclosures

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP, has the following relevant financial relationships:
Consultant or advisor for: Abbott; AstraZeneca; Amgen; Baxter Healthcare; Boehringer Ingelheim; Bristol Myers Squibb Company; Relypsa; Roche; Sanofi-Aventis; SC Pharmaceuticals; Vifor Pharma
Other: DSMB: LivaNova
Steering Committee Member: Relypsa; Renovacor

Nasrien Ibrahim, MD, FACC, FAHA, FHFSA

Advanced Heart Failure and Transplant Cardiologist
Massachusetts General Hospital
Harvard University Commonwealth Fund Fellow in Minority Health Policy
Harvard TH Chan School of Public Health
MPH in Health Policy Candidate
Boston, Massachusetts, United States

Disclosures

Nasrien Ibrahim, MD, FACC, FAHA, FHFSA, has the following relevant financial relationships:
Consultant or advisor for: Cytokinetics
Speaker or member of speakers bureau for: Medtronic

Martha Kingman, FNP, DNP

Nurse Practitioner
Pulmonary Services, Heart and Lung Center
University of Texas Southwestern Medical Center
Dallas, Texas, United States

Disclosures

Martha Kingman, FNP, DNP, has the following relevant financial relationships:
Consultant or advisor for: Aerovate; Gossamer Bio; Janssen; Johnson & Johnson; Liquidia; Merck; United Therapeutics

Mikhail Kosiborod, MD

Vice President, Research
Saint Luke's Health System
Professor of Medicine (Cardiology)
University of Missouri-Kansas City
Kansas City, Missouri, United States

Disclosures

Mikhail Kosiborod, MD, has the following relevant financial relationships:
Consultant or advisor for: Alnylam; Amgen; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Cytokinetics; Esperion; Janssen; Lexicon; Lilly; Merck; Novo Nordisk; Pharmacosmos; Sanofi; Vifor Pharma
Research funding from: AstraZeneca; Boehringer Ingelheim

Thomas M. Maddox, MD, MSc

Vice President, Digital Products and Innovation
BJC HealthCare/Washington University School of Medicine
Professor of Medicine (Cardiology)
Washington University School of Medicine
Trustee, American College of Cardiology
St Louis, Missouri, United States

Disclosures

Thomas M. Maddox, MD, MSc, has no relevant financial relationships.

Ahmad Masri, MD, MS

Director, Hypertrophic Cardiomyopathy Center
Director, Cardiac Amyloidosis Program
Assistant Professor of Medicine
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon, United States

Disclosures

Ahmad Masri, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Attralus; BridgeBio; Bristol Myers Squibb Company; Cytokinetics; Ionis; Tenaya
Research funding from: Akcea; Ionis; Pfizer; Ultromics

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Professor of Medicine, Thomas Jefferson University
Chief of Quality for the CV Line
Clinical Professor of Medicine, Central Michigan University
Adjunct Professor of Epi/Biostats
Case Western Reserve University
Detroit, Michigan, United States

Disclosures

Ileana Piña, MD, MPH, FAHA, FACC, FHFSA, has the following relevant financial relationships:
Consultant or advisor for: Vifor Pharma

Fatima Rodriguez, MD, MPH, FACC, FAHA

Assistant Professor in Cardiovascular Medicine
Stanford Prevention Research Center
Stanford, California, United States

Disclosures

Fatima Rodriguez, MD, MPH, FACC, FAHA, has the following relevant financial relationships:
Consultant or advisor for: Amgen (former); Healthpals; Novartis; Novo Nordisk

Brett W. Sperry, MD

Cardiologist
Associate Program Director
Advanced Heart Failure and Transplantation Fellowship
Co-Director, Institutional Review Board
Saint Luke's Mid America Heart Institute
Kansas City, Missouri, United States

Disclosures

Brett W. Sperry, MD, has the following relevant financial relationships:
Consultant or advisor for: Alnylam; BridgeBio
Speaker or member of speakers bureau for: Pfizer
Research funding from: Pfizer

Editors

Asha P. Gupta, PharmD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Joy P. Marko, MS, APN-C

Senior Medical Education Director, Medscape, LLC

Disclosures

Joy P. Marko, MS, APN-C, has no relevant financial relationships.

Cheryl Perkins, MD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Cheryl Perkins, MD, RPh, has disclosed no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Heart Failure and Myocardial Disease

Authors: Javed Butler, MD, MPH, MBA; Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA; Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC; Nasrien Ibrahim, MD, FACC, FAHA, FHFSA; Martha Kingman, FNP, DNP; Mikhail Kosiborod, MD; Thomas M. Maddox, MD, MSc; Ahmad Masri, MD, MS; Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA; Fatima Rodriguez, MD, MPH, FACC, FAHA; Brett W. Sperry, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 1/4/2023

Valid for credit through: 1/4/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Present and Future of Device-Based Care in HF

Where can devices play a role in the detection of worsening HF and management with medical therapy? Dr Butler shares his insights.
Javed Butler, MD, MPH, MBA

Optimizing GDMT Today: Are You Up to the Challenge?

How do you optimize the 4 pillars of guideline-directed medical therapy for HF? Find out Dr Ibrahim's strategies for success!
Nasrien Ibrahim, MD, FACC, FAHA, FHFSA

Newest Pillar in HF: What You Need to Know About SGLT2 Inhibitors

SGLT2 inhibitors are not just diabetes drugs anymore! Dr Kosiborod outlines their “full house” effect in patients with HFrEF, HFpEF, and acute HF.
Mikhail Kosiborod, MD

The Ever-Evolving Heart Failure Treatment Armamentarium: Focus on New and Emerging Strategies for Advanced Disease

It's a new era in the management of HF! Dr Piña discusses about future targets and approaches.
Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Breaking Ground in HFpEF Evolving Data and Treatment Options

Get an in depth look at the diagnosis and treatment of HFpEF. Dr Zieroth explains the complexities with HFpEF and discusses therapies that are phenotype-specific, with proven benefit, and on the horizon.
Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA

Unfolding the Mystery of ATTR: What Do HF Specialists Need to Know?

Not sure how to identify cardiac amyloidosis? Dr Sperry solves the mystery with this overview of the signs, diagnostic work up, and treatment.
Brett W. Sperry, MD

The Role of Digital Health in Heart Failure

How can digital health help with predicting HF decompensation and improving patient outcomes? Dr Maddox gives the download.
Thomas M. Maddox, MD, MSc

RV Dysfunction in My Patient: Approaches to Conquer the Diagnosis and Treatment

Pulmonary arterial hypertension can cause right ventricular dysfunction which leads to right heart failure and death. Dr Kingman explains strategies to lower your patient's risk for disease progression with appropriate diagnosis and early treatment. Time is of the essence!
Martha Kingman, FNP, DNP

New Heart Failure Guidelines

What's new in the 2022 ACC/AHA/HFSA guidelines for the management of HF? Learn about important updates from Dr Bozkurt, who is a leading author.
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC

Beyond a Thick Heart: New Horizons in HCM and Implications for Your Practice

Out with the old, in with the new! Dr Masri talks about new therapies that target the underlying pathophysiology of hypertrophic cardiomyopathy.
Ahmad Masri, MD, MS

Educational Impact Challenge

The goal of this activity is that learners will be better able to identify and manage patients with heart failure per new therapeutics and guideline-directed medical therapy (GDMT).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 13

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Co-Chair

Javed Butler, MD, MPH, MBA

Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC

Nasrien Ibrahim, MD, FACC, FAHA, FHFSA

Martha Kingman, FNP, DNP

Mikhail Kosiborod, MD

Thomas M. Maddox, MD, MSc

Ahmad Masri, MD, MS

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Fatima Rodriguez, MD, MPH, FACC, FAHA

Brett W. Sperry, MD

Editors

Asha P. Gupta, PharmD, RPh

Joy P. Marko, MS, APN-C

Cheryl Perkins, MD, RPh

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

CME / ABIM MOC / CE

Heart Failure and Myocardial Disease

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Co-Chair

Javed Butler, MD, MPH, MBA

Shelley Zieroth, MD, FRCPC, FCCS, FHFSA(hon), FESC, FACC, FHFA

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FESC

Nasrien Ibrahim, MD, FACC, FAHA, FHFSA

Martha Kingman, FNP, DNP

Mikhail Kosiborod, MD

Thomas M. Maddox, MD, MSc

Ahmad Masri, MD, MS

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Fatima Rodriguez, MD, MPH, FACC, FAHA

Brett W. Sperry, MD

Editors

Asha P. Gupta, PharmD, RPh

Joy P. Marko, MS, APN-C

Cheryl Perkins, MD, RPh

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Lisa Simani, APRN, MS, ACNP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Heart Failure and Myocardial Disease

Contents of This CME Activity

The Present and Future of Device-Based Care in HF

Optimizing GDMT Today: Are You Up to the Challenge?

Newest Pillar in HF: What You Need to Know About SGLT2 Inhibitors

The Ever-Evolving Heart Failure Treatment Armamentarium:​ Focus on New and Emerging Strategies for Advanced Disease​

Breaking Ground in HFpEF​ Evolving Data and Treatment Options

Unfolding the Mystery of ATTR:​ What Do HF Specialists Need to Know?​

The Role of Digital Health in Heart Failure

RV Dysfunction in My Patient: Approaches to Conquer the Diagnosis and Treatment​

New Heart Failure Guidelines

Beyond a Thick Heart​: New Horizons in HCM and Implications for Your Practice​

Educational Impact Challenge

The Ever-Evolving Heart Failure Treatment Armamentarium: Focus on New and Emerging Strategies for Advanced Disease

Breaking Ground in HFpEF Evolving Data and Treatment Options

Unfolding the Mystery of ATTR: What Do HF Specialists Need to Know?

RV Dysfunction in My Patient: Approaches to Conquer the Diagnosis and Treatment

Beyond a Thick Heart: New Horizons in HCM and Implications for Your Practice